β-内酰胺联合达托霉素对MSSA菌血症临床结局的影响:倾向评分匹配分析
匹配后BL/D-C组110例与BL-M组168例在7天、30天和90天全因死亡率均无显著差异。结论认为BL/D-C未能降低MSSA菌血症患者死亡率,亟需改善生存的治疗策略。
要点
- BL/D-C与BL-M在MSSA菌血症的7天、30天和90天全因死亡率均无显著差异。
- 匹配后7天死亡率8.18% vs 7.74%,30天17.3% vs 16.1%,90天22.7% vs 23.2%。
- 在高风险感染源及排除导管相关菌血症亚组中,BL/D-C同样未显示 mortality 获益。
核心结论
- β-内酰胺联合达托霉素未能降低MSSA菌血症患者的死亡率。
研究设计与样本
- 514例中排除164例(接受其他联合治疗、肺炎或入院48小时内死亡),剩余350例接受BL/D-C(136例)或BL-M(214例)。
- 采用1:2倾向评分匹配分析,匹配后BL/D-C组110例、BL-M组168例,使用Cox回归模型评估差异。
主要发现
- BL/D-C组患者Pitt评分更高且持续性菌血症更常见。
- 原始分析中两组死亡率无差异。
- 倾向评分匹配后,BL/D-C组与BL-M组7天全因死亡率分别为8.18%与7.74%(P=1.000),30天为17.3%与16.1%(P=.922),90天为22.7%与23.2%(P=1.000)。
- 在高风险感染源亚组及排除导管相关菌血症亚组中,死亡率亦无显著差异。
临床怎么用
- 对于MSSA菌血症,不应常规采用β-内酰胺联合达托霉素以期望降低死亡率。
- 仍需探索能改善MSSA菌血症生存的治疗策略。
局限性
- 回顾性队列设计可能存在残余混杂。
- BL/D-C组病情更重(Pitt评分更高、持续性菌血症更多),可能影响结果解释。
- 单中心研究,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mortality rates from Staphylococcus aureus bacteremia are high and have only modestly improved in recent decades. We compared the efficacies of a β-lactam in combination with daptomycin (BL/D-C) and β-lactam monotherapy (BL-M) in improving clinical outcomes in methicillin-susceptible S. aureus (MSSA) bacteremia. METHODS: A retrospective cohort study of MSSA bacteremia was performed in a tertiary hospital from January 2011 to December 2017. Patients receiving BL/D-C and BL-M were compared to assess 7-, 30-, and 90-day mortality rates. A 1:2 propensity score matching analysis was performed. Differences were assessed using Cox regression models. RESULTS: Of the 514 patients with MSSA bacteremia, 164 were excluded as they had received combination therapies other than BL/D-C, had pneumonia, or died within 48 hours of admission. Of the remaining 350 patients, 136 and 214 received BL/D-C and BL-M, respectively. BL/D-C patients had higher Pitt scores and persistent bacteremia more often than BL-M patients. In the raw analysis, there were no differences in mortality rates between groups. After propensity score matching, there were no significant differences between the BL/D-C (110 patients) and BL-M (168 patients) groups for all-cause mortality rates at 7 days (8.18% vs 7.74%; P = 1.000), 30 days (17.3% vs 16.1%; P = .922), and 90 days (22.7% vs 23.2%; P = 1.000), even in a subanalysis of patients with high-risk source of infection and in a subgroup excluding catheter-related bacteremia. CONCLUSIONS: BL/D-C failed to reduce mortality rates in patients with MSSA bacteremia. Treatment strategies to improve survival in MSSA bacteremia are urgently needed.
引用
- Grillo S, Cuervo G, Carratalà J, et al. Impact of β-Lactam and Daptomycin Combination Therapy on Clinical Outcomes in Methicillin-susceptible Staphylococcus aureus Bacteremia: A Propensity Score-matched Analysis. Clin Infect Dis. 2019. PMID: 30615122. doi:10.1093/cid/ciz018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。